{"id":"W2126978426","doi":"10.1007/s00125-010-1804-y","title":"Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials","year":2010,"lang":"en","type":"article","venue":"Diabetologia","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":180,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"GlaxoSmithKline","keywords":"Rosiglitazone; Medicine; Metformin; Internal medicine; Glibenclamide; Diabetes mellitus; Adverse effect; Type 2 diabetes; Sulfonylurea; Clinical trial; Gliclazide; Hazard ratio; Cancer; Endocrinology; Insulin; Confidence interval","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01121206,0.00026247,0.002097998,0.0000989125,0.00004581619,0.00002575085,0.0002146004,0.0003163099,0.000004502297],"category_scores_gemma":[0.005796337,0.0001533988,0.0004353081,0.0001611951,0.0004220192,0.00001837549,0.00006403398,0.000175776,6.481793e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000006532875,"about_ca_system_score_gemma":0.00007119556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000154997,"about_ca_topic_score_gemma":0.00004239625,"domain_scores_codex":[0.9963398,0.001073124,0.001482455,0.0004774477,0.0002777267,0.0003494481],"domain_scores_gemma":[0.9974543,0.00118386,0.0006342112,0.0004967263,0.0001714732,0.00005943913],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0286878,0.0002006764,0.8093903,0.0001600075,0.0004230365,4.163054e-7,0.0003310029,0.00001341188,0.1019766,0.00003950594,0.00001183851,0.05876544],"study_design_scores_gemma":[0.4980848,0.001843881,0.2869139,0.0001830969,0.0007423183,5.79728e-7,0.0005173139,0.0006675175,0.2096457,0.0003090389,0.0005443593,0.0005475217],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9677022,0.02844762,0.00003788802,0.0000210671,0.0003018882,0.003455575,0.00001905957,0.000007349309,0.000007323002],"genre_scores_gemma":[0.9960546,0.001584547,0.0008714468,0.00005938198,0.00006632925,0.001308679,0.00003111752,0.00001909402,0.000004757946],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5224764,"threshold_uncertainty_score":0.6939175,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04647858839311374,"score_gpt":0.3676919514426077,"score_spread":0.321213363049494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}